The bone microenvironment (e.g. glycosaminoglycans (GAGs), growth factors) plays a major role in bone resoption, especially in the formation of osteoclast which differentiate from the hematopoietic lineage in the presence of RANKL. Previous studies revealed that GAGs may influence osteoclastogenesis, but data are very controversial, some studies showing an inhibitory effect of GAGs on osteoclastic differentiation whereas others demonstrated a stimulatory effect. To clarify their activities, we investigated the effect of 5 families of GAGs in three different models of human/mouse osteoclastogenesis. The present data revealed that heparin inhibited osteoclastogenesis in these 3 models, which was confirmed by a decrease in mRNA expression of osteoclastic markers and by an inhibition of the bone resorption capacity. We also demonstrated in RAW 264.7 cells that other families of GAGs different from heparin inhibited RANKL-induced osteoclastogenesis, and that this inhibition was dependent on the length and the level of sulfation of GAGs. In the present work, heparin did not bind to RANKL and did not modulate RANKL signaling. Heparin acted at 2 distinct steps of osteoclastogenesis from human CD14 + cells: first, heparin strongly decreased the adherence of osteoclast precursors, and secondly inhibited osteoclasts to spread and to be active. Furthermore, the second action of heparin was reversible as the removal of heparin at the end of the culture time allowed the condensed cells to spread out and showed the formation of morphological active osteoclasts. The present work clearly evidences that GAGs inhibit osteoclastogenesis in vitro and strengthens the therapeutic interest of defined GAGs in osteolytic diseases.
Introduction
Bone metabolism is regulated by a functional balance between catabolic and anabolic activities of bone cells. Thus, osteoclasts are multinucleated cells specialized in bone catabolism which participate to phosphocalcic homeostasis together with cells playing anabolic functions named osteoblasts. Osteoclasts originate from the monocyte/macrophage lineage through a series of events associating membranous, soluble and extracellular matrix compounds (Bruzzaniti et al, 2006) . Among these factors, some are required for proliferation and differentiation of osteoclast progenitors such as macrophage-colony stimulating factor (M-CSF) (Biskobing et al, 1995; Felix et al, 1990; Witkor-Jedrzejcak et al, 1990 ) while other factors such as receptor activator of nuclear factor kB ligand (RANKL) are more specifically involved in the commitment of mononuclear precursors to the fusion and formation of multinucleated resorbing osteoclasts . In this system, RANKL expressed by osteoblasts and stromal cells binds to its receptor RANK expressed at the surface of osteoclast precursors and consequently activates specific signal pathways leading to the formation, maturation and survival of osteoclasts (Boyle et al, 2003; Wittrant et al, 2004) . Furthermore, the RANKL/RANK activities are controlled by osteoprotegerin (OPG) which acts as a soluble decoy receptor blocking the binding of RANKL to RANK, subsequently reducing osteoclastogenesis and bone resorption (Simonet et al, 1997; Yasuda et al, 1998) .
Extracellular matrix components such as glycosaminoglycans (GAGs) also participate to bone metabolism . GAGs are linear polymers which are bound to a core protein to form proteoglycans . GAGs are composed of repeated disaccharidic units of hexosamine and hexuronic acid, except for keratan sulfate in which hexuronic acid is replaced by galactose. According to the epimerization of hexosamine and uronic acid, several families of GAGs have been established. Proteoglycans and GAGs contribute to the maintenance of bone mass through their involvement in collagen organization (Corsi et al, 2002) . They could exert several activities on bone cells as co-factors in cell-to-cell adhesion, or to modulate the binding and activation of several growth factors or receptors such as OPG by syndecan-1 (Bernfield et al., 1999; Hildebrand et al., 1994; Robinson et al., 2005; Mosheimer et al., 2005; Standal et al., 2002) . Unfortunately, the data available on the effects of GAGs on osteoclastogenesis are very limited and controversial. For example, Ariyoshi et al. (2005) showed that hyaluronic acid, the most abundant GAG in mammalian tissues, enhances osteoclast formation and function, whereas in 2007, Chang et al. described an opposite effect on osteoclastogenesis. Irie et al. (2007) recently demonstrated that heparin in combination with 1,25(OH) 2 D3/PGE2 enhances the pit-forming activity of osteoclasts obtained from the coculture of mouse osteoblasts with bone marrow cells.
However, they did not observe any direct effect of heparin on osteoclastogenesis. On the other hand, Shinmyouzu et al. (2007) , demonstrated that high concentrations of dermatan sulfate inhibit osteoclastogenesis, and the same group showed similar activities with heparin (Ariyoshi et al, 2008) . The authors suggested that GAGs act through an inhibition of RANKL signaling (inhibition of p38 and ERK phosphorylation following RANKL stimulation) to achieve their inhibitory effect on osteoclastogenesis. Moreover, these controversial findings on GAG effects on osteoclastogenesis are strengthened by the study of Folwarczna et al. (2005) who pointed out species differences in the sensitivity of bone marrow cells to standard and low-molecular weight heparins. For instance, in a rat model, low concentrations of heparin increased the formation of osteoclasts, whereas it decreased with the highest concentrations. In mouse bone marrow cell cultures, heparin suppressed the formation of osteoclasts, with the exception of low concentrations of standard heparin which intensified this process (Folwarczna et al, 2005) .
In this high controversial context, the aim of our study was to clarify the direct effect of GAGs on osteoclastogenesis using three different cellular models: murine RAW 264.7 monocytic cell line, murine purified CD11b + cells and human purified CD14 + monocytes.
These models are characterized by the absence of osteoblastic/stromal cells, allowing us to investigate the direct effect of GAGs on osteoclast precursors. GAGs from various origins (bovine and porcine heparins with different sulfation levels, heparan-, chondroitin-and dermatan-sulfate, hyaluronic acid and oligosaccharides of different lengths) were assessed in in vitro osteoclastogenesis models.
Materials and methods

Materials
Human M-CSF (hM-CSF), mouse M-CSF (mM-CSF) and human OPG (hOPG) were obtained from R&D Systems (Abington, UK (Lyon et al, 2000) . (Duplomb et al, 2008) . At day 3 of the culture, medium was changed for fresh medium containing 10% FCS, 25 ng/ml hM-CSF and 100 ng/ml hRANKL, with or without heparin (5 µM). Then medium was changed every 4 days. The formation of osteoclasts occurred after around 15 days and was observed by TRAP staining. In some experiments, heparin was added at different time points of the culture period, as indicated. To test the capacity of osteoclasts to resorb bone, CD14 + cells were cultured on dentine slices in the conditions previously described. At the end of the culture period, osteoclasts were removed by bleach; dentin slices were fixed with 4% glutaraldehyde in 0.2 M sodium cacodylate solution for 30 minutes, followed by staining with 1% toluidine blue in 0.5% sodium tetraborate solution for 3 minutes (Chu et al, 2006) . Resorption lacunae were identified by light stereomicroscopy (Zeiss, STEMI 2000-C, Göttingen, Germany) and resorbed surfaces were measured using QWin software (Leica, France). To determine the effect of heparin of mature osteoclasts, we used a technique established by Fuller et al (2006) .
Osteoclastogenesis assays
Briefly, after formation of osteoclasts as described above, the medium was removed and the cell layer washed three times with PBS without calcium and magnesium. Six hundred microliters of 0.02% EDTA were added per well (6-well plate) and cells were incubated for 20 min at room temperature.EDTA was then removed from the dish and replaced with 600 µl of calcium/magnesium-free PBS. A cell scraper was used to scrape the cells in PBS, and the resulting cell suspension was mixed using a pipette to ensure uniform cell dispersal. Two hundred and fifty microliters of this cell suspension were added to each well (24-well plate) on a dentin slice in 250 µl αMEM, 10% FCS. Cells were allowed to sediment for 20 min at 37°C before dentin slices were washed. Cells were incubated in 300 µl αMEM, 10% FCS in the presence or the absence of heparin. After incubation, bone resorption was assessed as described above.
Adherence of CD14 + cells was analyzed by counting the adherent cells after 3 days of culture in the presence of hM-CSF (25 ng/ml) with or without heparin (5 µM). Briefly, cells
were washed 3 times with PBS (Lonza, Verviers, Belgium) and adherent cells were detached with trypsin solution (Lonza); cells were counted using trypan blue exclusion.
Dendritic differentiation was obtained upon stimulation with 5 ng/ml hIL-4 (Invitrogen)
+ 100 ng/ml human GM-CSF (kindly provided by UTCG, CHU Nantes) (Sallusto and Lanzavecchia, 1994) . Briefly, 1 x 10 6 CD14 + cells or PBMCs were cultured in 6-well plates in 
Surface plasmon resonance-binding assay
Experiments were carried out on a BIAcore 3000 instrument (Biacore, Sweden).
RANKL (2 µg/mL) in 5 mM maleate, pH 5.75 was covalently immobilized to the dextran matrix of a CM5 sensor chip (BIAcore) at a flow rate of 5 µl/min. Immobilization levels in the range of? 4000 RU were obtained. Binding assays were performed at 25°C in 10 mM Hepes buffer, pH 7.4, containing 0.15 M NaCl and 0.005% P20 surfactant (HBS-P buffer, BIAcore) at a flow rate of 30 µl/min for heparin (1 to 20 nM) and 20 µl/min for hOPG (25nM). The resulting sensorgrams were fitted using BiaEval 4.1 software (Biacore).
Western Blot Analysis
After 5 hours of culture in serum-free medium, undifferentiated CD14 + cells were stimulated with 100 ng/ml of hRANKL for 15 minutes at 37°C in the presence or absence of 125 µg/ml heparin. Cell lysates were obtained and protein concentrations were determined as described previously (Duplomb et al., 2008) . Proteins were run on 10% SDS-PAGE gels and transferred to Immobilon-P membranes (Millipore, USA) which were then incubated with antibodies to Phospho-ERK1/2, Phospho-p38, Phospho-p105, Total-ERK1/2, Total-p38 and Total-p105 (Cell Signaling Technologies, USA). Bands were visualized using ECL reagent (Roche, Germany).
Statistical analysis
Each experiment was repeated in triplicate three times independently. The mean + SD was calculated for all conditions and compared by ANOVA. Differences relative to a probability of two-tailed p < 0.05 were considered significant. inhibited RANKL-induced osteoclastogenesis (76%, p<0.01). Heparin had no effect on the proliferation of CD14 + cells cultured in the presence or absence of M-CSF for 3 or 6 days (aditional data 1). Furthermore, when cultured on dentine slices, TRAP + osteoclasts showed a strong capacity of resorption ( Figure 2C ) which was significantly reduced in the presence of heparin ( Figure 2D , p<0.05). Similar experiments were performed using mature osteoclasts isolated from differentiated RANKL-CD14+ cell cultures, and in this context heparin had no effect on dentin resorption (data not shown).
Results
Glycosaminoglycans inhibit RANKL-induced osteoclastogenesis in murine and
To investigate the effect of other GAG families on RANKL-induced osteoclastogenesis, heparan sulfate (bovine and porcine origin), chondroitin sulfate and dermatan sulfate at a concentration of 5 µM were added to the culture of RAW 264.7 cells.
After 5 days, all the GAGs tested inhibited RANKL-induced osteoclastogenesis between 65
and 80% ( Figure 3A ) while GAGs alone had no effect on the RAW 264.7 cell line (at the proliferation or apoptosis levels) and did not reveal any cell toxicity (data not shown).
Furthermore, addition of heparin-derived oligosaccharides [4, 14 and 24 (corresponding respectively to 4, 14 and 24 disaccharide-unit length)] to the culture inhibited RANKL-induced osteoclastogenesis in a dose-and size-dependent manner ( Figure 3B ).
Indeed, 1.56 µM of oligosaccharide 4 inhibited osteoclastogenesis by 6%, whereas at the same concentration oligosaccharides 14 and 24 inhibited osteoclastogenesis by respectively 24% and 53%. In the same way, inhibition of RANKL-induced osteoclastogenesis using 12.5 µM oligosaccharide was around 17% with oligosaccharide 4, 44% with oligosaccharide 14, and 72% with oligosaccharide 24. At 100 µM, osteoclastogenesis was almost totally abolished with all oligosaccharides, whatever their size. These oligosaccharides had no effect on RAW 264.7 cells cultured in medium without RANKL. We then analyzed the effect of hyaluronic acid which is a huge non-sulfated molecule. As shown in figure 3C , hyaluronic acid also inhibited osteoclastogenesis in a dose dependent manner.
Sulfation of oligosaccharides is a key parameter for the inhibition of RANKL-induced osteoclastogenesis
To decipher the mechanisms involved in the inhibition of osteoclastogenesis observed in the presence of oligosaccharides and GAGs, we analyzed the importance of quantitative and qualitative sulfation by comparing the effects of normal standard heparin with several forms of specifically desulfated heparins on N-or O-residues: de-N-sulfated re-N-acetylated heparin, completely desulfated heparin, de-2O-sulfated heparin, de-6O-sulfated heparin, and de-N-sulfated heparin. As shown in figure 4, RANKL-induced osteoclastogenesis was inhibited by normal heparin (83% of inhibition, p<0.01), by de-N-sulfated re-N-acetylated and de-N-sulfated heparins (around 50% of inhibition), and by de-2O-and de-6O-sulfated heparins (around 75% of inhibition, p<0.01). However, totally desulfated heparin poorly inhibited RANKL-induced osteoclastogenesis (around 14%; p<0.05).
GAGs induce differentiation of human monocytes into dendritic cells
To determine whether the inhibitory activity of GAGs was specific of osteoclastogenesis, the effects of heparin-derived oligosaccharide 16 (32-mer), dermatan sulfate and heparin were investigated during the differentiation process of human monocytes into dendritic cells (non adherent cells) using two different approaches: isolated CD14 + monocytes ( Figure 5A ) or monocytes obtained after 2h of adherence of total PBMCs ( Figure   5B ). As shown in figure Figure 5A ). The same effect was observed using total PBMCs: oligosaccharide 16, dermatan sulfate and heparin significantly increased the dendritic cell differentiation with a mean average of about 12.5% ( Figure 5B ) whereas these GAGs/oligosaccharides have no effect alone. Thus the inhibitory effect of GAGs observed on osteoclast differentiation is specific to this commitment because no inhibition could be shown with other differentiation systems such as dendritic cell differentiation.
Heparin does not bind to RANKL and does not modulate RANKL signaling
Shinmyouzu et al. demonstrated that dermatan sulfate inhibits RANKL-induced osteoclastogenesis in a mouse model of osteoclast differentiation from bone marrow (Shinmyouzu et al., 2007) . They showed that this inhibition occurred through the binding of dermatan sulfate to RANKL leading to the inhibition of RANKL interaction to its receptor RANK, and thus to the inhibition of RANKL signaling. Based on these observations, the authors suggested that the same phenomenon could be involved in the inhibition of RANKLinduced osteoclastogenesis which they also observed with heparin or chondroitin sulfate E. In the present work, surface plasmon resonance experiments demonstrated that heparin did not bind to RANKL ( Figure 6A Figure 6B ).
Heparin inhibits the adherence and spreading of osteoclasts and thus their functionality
To better characterize the mechanisms by which heparin inhibits osteoclast formation, especially in the early adherence and spreading phases, the effect of heparin was assessed at different times during the culture period. When heparin was added during the first 4 days (D0-D4) of culture in the presence of M-CSF only very few osteoclasts were generated after 14 days ( Figure 7A ). Moreover, when heparin was added during the first 4 days, it inhibited by around 40% the number of adherent CD14 + osteoclast precursors compared to the control condition ( Figure 7B ). Thus in this culture condition, fewer osteoclast precursors adhered to the plastic surface and less osteoclasts were generated in the presence of RANKL at D14. The addition of heparin during intermediate culture step (D4-D10) did not inhibit osteoclast formation, and the number of osteoclasts formed was similar to the control group in the presence of RANKL ( Figure 7A ). In contrast, when heparin was added during the fusion step of osteoclastogenesis (D10-D14), heparin inhibited significantly the number of osteoclast formed ( Figure 7A ).
In and seemed multinucleated, we suggested that heparin inhibited the spreading of RANKLgenerated osteoclasts. Such modifications of cell morphology were not observed in the presence of OPG ( Figure 7D ). Thus, after the formation of large osteoclasts in the control medium containing RANKL (after 14 days), heparin was maintained (D4-D17) or removed (D4-D14) and the cells cultured for 3 more days. Osteoclasts did not die during this additive period and surprisingly, the number of condensed cells decreased whereas the number of large osteoclasts increased, suggesting a recovery of the spreading of the initially condensed cells during these 3 days ( Figures 7C and 7D ). We confirmed this phenomenon using time laps experiment. The same protocol was performed and a picture was taken every 10 min during 11 hours to create a time lapse movie (aditional data 2-4). These movies showed that condensed cells observed in the presence of RANKL and heparin recovered spreading ability when heparin was removed of the culture.
These result clearly demonstrated a sequential effect of heparin on RANKL-induced osteoclastogenesis. Heparin acted at two distinct levels of osteoclastogenesis: i) at the early steps of the process by affecting and decreasing cell adherence and ii) at the end of the osteoclastogenesis process by inhibiting the spreading of the preformed osteoclasts, which were no more functional as shown by the inhibition of their ability to resorb dentine substrate.
Furthermore, as shown in figures 7C and 7D, this second effect is reversible as condensed osteoclasts are able to spread again when heparin was removed only 3 days after the predicted end of the culture. In summary, these results suggest that heparin did not inhibit the fusion of osteoclast precursors (CD14 + monocytes), but induced a morphological change of the generated osteoclasts leading to an inhibition of the functionality of these cells.
Discussion
Bone is a connective tissue composed of cells and mineralized extracellular matrix. Its normal remodeling and volume are maintained through the balance of bone formation by osteoblasts and resorption by osteoclasts. Although this equilibrium between osteoblast and osteoclast activities is controlled by a plethoric number of cytokines and growth factors, components of the extracellular matrix including proteoglycans and glycosaminoglycans (GAGs) are also involved in this phenomenon . Indeed, heparan sulfate proteoglycans are found ubiquitously on both the surface of cells as well as within the extracellular matrix where they bind and modify the function of numerous ligands . The influence of GAGs on bone metabolism has been revealed many years ago by long-term administration of heparin which can lead to the development of osteoporosis. Rats treated once daily by subcutaneous injections of heparin exhibited decreased trabecular bone volume both by decreasing the rate of bone formation and increasing the rate of bone resorption (Muir et al, 1996) . Similarly, Barbour et al. (1994) showed that 36% of pregnant women undergoing long-term treatment with heparin had a 10% reduction in femoral bone mineral density. However, the mechanism sustaining this osteoporosis was unclear and it was difficult to determine if these effects on bone resorption were due to the direct effect of heparin on osteoclasts or indirectly via its osteoblast activity.
This study takes place in this context and analyzes the influence of GAGs on osteoclastogenesis and resorption activity.
The effect of GAGs on osteoclastogenesis is controversial, as some studies showed a stimulation of osteoclastogenesis (Irie et al, 2007; Fuller et al, 1991) and others an inhibition (Shinmyouzu et al, 2007; Ariyoshi et al, 2008) . It has been suggested that the mechanisms of action of GAGs on osteoclasts involved the inhibition of OPG, the decoy receptor for RANKL (Irie et al, 2007) , or a direct interaction with RANKL leading to its inactivation (Shinmyouzu et al, 2007; Ariyoshi et al, 2008) . It is worth noting that there are differences in the models used by these two teams. Indeed, Irie et al., used a system of coculture of mouse bone marrow with calvarial osteoblasts in a medium supplemented with 1,25(OH) 2 D3/PGE2 (Irie et al, 2007) whereas Shinmyouzu et al. (2007) performed their studies on mouse bone marrow cells alone. To better understand the precise role of GAGs on osteoclastogenesis, we used three different models of osteoclastogenesis (murine or human) and various tested
GAGs. Our results clearly demonstrated that all GAGs inhibited osteoclastogenesis in all systems tested. Furthermore, we demonstrated the importance of the length and the sulfation of the GAGs in their inhibitory effect. Such structural significance has been already shown in other biological models (Hallak et al, 2000; McDonnell et al, 2004; Rajgopal et al, 2008) . The influence of GAG length on osteoclastogenesis has been also suggested by in vivo study.
Indeed, in contrast to unfractioned heparin which seems to decrease bone formation and increase bone resorption, low molecular weight heparins cause less bone loss because they only decrease bone formation and have no effect on bone resorption (Rajgopal et al, 2008) .
The sulfation also plays a key role in GAGs biological activities, as revealed by the present work. The sulfation has clearly been shown to participate to the control of cell biology. as growth factors or enzymes Gallagher, 2006) . Similarly, osteoclast differentiation and activity are regulated by GAGs at different levels, as revealed in previous studies. For instance, in an in vitro model of osteoclastogenesis, FGF-2 upregulated the expression of RANKL on rheumatoid arthritis synovial fibroblasts which was diminished by the removal of heparan sulfate with heparatinase (Nakano et al, 2004) . Heparan sulfate can also participate in bone resorption regulation through the inhibition of cathepsin K activity, as demonstrated by the study of Li et al. (2004) . Cathepsin K is a lysosomal papain-like cysteine protease mainly involved in bone matrix destruction that forms complexes with chondroitin sulphate. If sulfation clearly modulates GAG activities on osteoclastogenesis, their length appears to be another key parameter in their biological functions. Indeed, although hyaluronic acid is not sulfated , its large size can explain its inhibitory activity on osteoclastogenesis. These data then revealed a complementary influence of length and sulfation of GAGs on osteoclastogenesis. We also have obtained some evidence that heparin and other GAGs inhibit osteoblast differentiation of bone marrow mesenchymal stem cells in vitro (unpublished data), demonstrating that GAGs exert their activities on osteoclasts as well as on osteoblasts. Overall, our data are in favour of a direct inhibitory activity of GAGs on osteoclastogenesis, and the effect of unfractionated heparin observed in vivo may be explained by its effects on the bone osteoblast compartment and subsequently by the dysregulation of the balance between osteoblasts and osteoclasts or by a slow down of bone remodeling.
However, how can we explain the strong discrepancies between previous published data? First, the models used were different and the present work is the first comparing simultaneously the GAG effects on human and murine cells (purified primary culture cells and cell lines). Ariyoshi et al. (2008) previously had shown that hyaluronic acid upmodulates osteoclastogenesis through activation of CD44 signaling pathway whereas Chang et al. (2007) demonstrated opposite effects revealing an activation of TLR4 signaling pathway without any involvement of CD44. However, the present work did not show any evidence for alteration in the RANK/RANKL signaling pathway and no specific induction of other signaling pathways has been observed after GAG treatments. Ariyoshi et al. (2008) demonstrated the binding of heparin to RANKL, but our experiments using surface plasmon resonance methodology did not confirm such binding, in contrast for instance to OPG, a heparin binding protein [data not
shown, (Theoleyre et al, 2006; Lamoureux et al, 2009) ]. Moreover, Shinmyouzu et al. (2007) published that dermatan sulfate inhibits osteoclast formation by binding to RANKL.
However, these authors used non relevant physiological concentrations of dermatan sulfate (300 µg/ml) and non purified osteoclast precursors to study osteoclastogenesis. Such effects may be due to the activation of Toll-like receptors as shown by Chang et al. (2007) . In this context, i.e. the absence of RANKL-GAG binding and signalisation, we analyzed the effects of GAGs on adhesion and fusion of osteoclast precursors. Thus, the second major finding of this study is the morphological changes induced by heparin on the cells obtained in the presence of RANKL. First, these cells can not be counted as active osteoclasts because the number of nuclei is less than 3, and second, these cells are not able to resorb dentine, indicating that they can be considered as immature osteoclasts or as non resorbing-osteoclasts.
However, this effect is reversible by removing heparin from the culture medium and few hours only are needed to get normal osteoclasts. We clearly showed that GAGs inhibit the osteoclast precursor adhesion, as well as the step of cell fusion. The alteration of cell adhesion and morphology avoids the cell fusion of osteoclast precursors and blocks osteoclast resorption, which is particularly sensitive to cell morphology to develop their brush border (Rousselle and Heymann, 2002 ).
The present work evidences a novel mechanism of action of GAGs on osteoclasts and their precursors. However, although a direct activity of GAGs on osteoclasts has been demonstrated, the mechanisms of action of low molecular weight heparin which have gradually replaced the use of unfractionated heparin in part due a lower risk of inducing osteoporosis, are not yet totally elucidated (Rajgopal et al, 2008) . Indeed, if short oligosaccharides are less efficient to inhibit osteoclastogenesis, the effect of low molecular weight heparins on osteoblasts and on osteoblast-osteoclast communications needs to be investigated. Moreover, complementary studies to determine whether the effects of heparin on bone are reversible are needed. Experiments were performed at least 3 times in triplicate (* p<0.05, ** p<0.01). µl/min and 20 µl/min, respectively, over the immobilized-RANKL sensorchip for 6 min. In a pH 7.4 buffer, hOPG but not heparin binds to hRANKL. (B) Human CD14 + monocytes were incubated for 15 min at 37°C with 100 ng/ml hRANKL in the presence or the absence of 5 µM heparin. Protein lysates were prepared and expression of Phospho-ERK1/2, total-total-ERK1/2, Phospho-p38, total-p38, Phospho-p105, total-p105 was analyzed by western blotting. All experiments were repeated three times, and a representative blot is shown. Aditional data 2-4 CD14 + monocytes were cultured in a 24-well plate with hM-CSF and hRANKL as described in the present paper, and with our without heparin (5 µM). At the end of the culture, heparin was removed or not from the medium and the culture was extended for 11 more hours. A picture was taken every 10 minutes during 11 hours, and the movies were reconstituted using the ImageJ software. 
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